The PVSG/WHO versus the Rotterdam European clinical, molecular and pathological diagnostic criteria for the classification of myeloproliferative disorders and myeloproliferative neoplasms (MPD/MPN): From Dameshek to Georgii, Vainchenker and Michiels 1950-2018
Open Access
- 17 April 2019
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 2 (1), 027-050
- https://doi.org/10.29328/journal.ijbmr.1001004
Abstract
No abstract availableThis publication has 123 references indexed in Scilit:
- The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraBlood, 2007
- Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disordersJournal of Thrombosis and Haemostasis, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisThe New England Journal of Medicine, 2007
- The Myeloproliferative DisordersThe New England Journal of Medicine, 2006
- Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutationBlood, 2006
- JAK2V617F: prevalence in a large Chinese hospital populationBlood, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Chronic Myeloproliferative Disorders in Bone Marrow BiopsiesPathology - Research and Practice, 1990
- Determination of Serum Immunoreactive Erythropoietin in the Investigation of ErythrocytosisThe New England Journal of Medicine, 1986
- Zwei Fälle von Leukämie mit eigenthümlichem Blut- resp. KnochenmarksbefundVirchows Archiv A Pathological Anatomy and Histopathology, 1879